Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real …
S Gupta, RSP Huang, J Stanke, O Hamdani, O Gjoerup… - 2022 - ascopubs.org
547 Background: There is an unmet need to identify metastatic urothelial carcinoma (mUC)
patients who might be spared chemotherapy in 1st line. Anti-PD-(L) 1 immune checkpoint …
patients who might be spared chemotherapy in 1st line. Anti-PD-(L) 1 immune checkpoint …
Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma
RP Graf, V Fisher, RSP Huang, O Hamdani… - JCO Precision …, 2022 - ascopubs.org
PURPOSE In real-world settings, patients with metastatic urothelial carcinoma (mUC) are
often more frail than clinical trials, underscoring an unmet need to identify patients who …
often more frail than clinical trials, underscoring an unmet need to identify patients who …
Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma
D Makrakis, R Talukder, GI Lin… - Clinical genitourinary …, 2022 - Elsevier
Background Sites of metastasis have prognostic significance in advanced urothelial
carcinoma (aUC), but more information is needed regarding outcomes based on metastatic …
carcinoma (aUC), but more information is needed regarding outcomes based on metastatic …
[HTML][HTML] First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and …
K Mori, B Pradere, M Moschini, H Mostafaei… - European Journal of …, 2021 - Elsevier
Introduction Platinum-based combination chemotherapy is the standard treatment for
patients with chemotherapy-eligible metastatic urothelial carcinoma (mUC). Immune …
patients with chemotherapy-eligible metastatic urothelial carcinoma (mUC). Immune …
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
TH Tsai, PJ Su, SY Huang, MC Kuo, CT Lin, CC Wu… - BMC cancer, 2023 - Springer
Background While the treatment guidelines have been established for pure urothelial
carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective …
carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective …
Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the Meet-Uro Group …
Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for
metastatic urothelial cancer (mUC) after the failure of previous platinum-based …
metastatic urothelial cancer (mUC) after the failure of previous platinum-based …
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study
Objectives Immune checkpoint inhibitors (ICIs) are indicated for metastatic urothelial cancer
(mUC), but predictive and prognostic factors are lacking. We investigated clinical variables …
(mUC), but predictive and prognostic factors are lacking. We investigated clinical variables …
First-line chemotherapy response is associated with clinical outcome during immune checkpoint inhibitor treatment in advanced urothelial carcinoma: a real world …
JR Li, SS Wang, K Lu, CS Chen, CL Cheng… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Immune checkpoint inhibitors (ICI) have become important tools for the
treatment of advanced urothelial carcinoma (aUC). However, the clinical strategy using ICIs …
treatment of advanced urothelial carcinoma (aUC). However, the clinical strategy using ICIs …
Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors …
A Rizzo, V Mollica, F Massari - European Urology Focus, 2022 - Elsevier
Abstract Context Immune checkpoint inhibitors (ICIs) have reported durable responses in
selected groups of patients with metastatic urothelial carcinoma (mUC). However …
selected groups of patients with metastatic urothelial carcinoma (mUC). However …
[HTML][HTML] Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
J Ruiz-Bañobre, A Molina-Díaz, O Fernández-Calvo… - ESMO open, 2021 - Elsevier
Background Few studies have investigated the safety and efficacy of anti-PD-(L) 1
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …
相关搜索
- checkpoint inhibitor predictive biomarker
- checkpoint inhibitor urothelial carcinoma
- chemotherapy benefit predictive biomarker
- checkpoint inhibitor chemotherapy benefit
- chemotherapy in the treatment urothelial carcinoma
- checkpoint inhibitors clinical outcomes
- meta analysis urothelial carcinoma
- checkpoint inhibitors sites of metastasis
- checkpoint inhibitors retrospective analysis
- checkpoint inhibitors meet uro
- prognostic factors urothelial carcinoma
- clinical outcome chemotherapy response
- meta analysis chemotherapy in the treatment
- retrospective analysis clinical outcomes
- meta analysis combination therapy
- retrospective analysis meet uro